Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totaling 16,980 shares, a drop of 97.0% from the July 15th total of 569,675 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily volume of 555,531 shares, the short-interest ratio is presently 0.0 days.

Bluejay Diagnostics Stock Down 1.0%

NASDAQ BJDX traded down $0.01 during trading hours on Thursday, hitting $1.04. The company had a trading volume of 166,338 shares, compared to its average volume of 2,501,006. The firm has a market cap of $1.08 million, a P/E ratio of -0.09 and a beta of 0.89. Bluejay Diagnostics has a fifty-two week low of $0.83 and a fifty-two week high of $16.68. The business has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $2.23.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88.

Insiders Place Their Bets

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the sale, the insider directly owned 92,055 shares of the company’s stock, valued at approximately $128,877. This represents a 27.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Institutional investors own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BJDX shares. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.